Abstract
Ganglioside complexes (GSCs) are known as target antigens in Guillain-Barré syndrome (GBS). To elucidate the clinical importance of the anti-GSC antibodies in GBS, we investigated serum antibodies to GSCs containing two of the gangliosides, GM1, GD1a, GD1b and GT1b, and analyzed clinical features of anti-GSC-positive GBS patients. Thirty-nine (17%) of 234 GBS patients had IgG anti-GSC antibodies. Anti-GSC-positive GBS had antecedent gastrointestinal infection and lower cranial nerve deficits more frequently than control GBS. The presence of antibody specificity to GD1a/GD1b and/or GD1b/GT1b was significantly associated with severe disability and a requirement for mechanical ventilation.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Autoantibodies / blood*
-
Campylobacter Infections / complications
-
Campylobacter jejuni
-
Cranial Nerve Diseases / complications
-
Disability Evaluation
-
Electrophysiology
-
Female
-
G(M1) Ganglioside / analogs & derivatives
-
G(M1) Ganglioside / immunology
-
Gangliosides / immunology*
-
Gastrointestinal Diseases / complications
-
Guillain-Barre Syndrome / complications
-
Guillain-Barre Syndrome / immunology
-
Guillain-Barre Syndrome / physiopathology*
-
Guillain-Barre Syndrome / therapy
-
Humans
-
Immunoglobulin G / immunology
-
Immunosorbent Techniques
-
Male
-
Middle Aged
-
Respiration, Artificial
-
Severity of Illness Index
Substances
-
Autoantibodies
-
Gangliosides
-
Immunoglobulin G
-
ganglioside GD1alpha
-
ganglioside, GD1b
-
G(M1) Ganglioside
-
trisialoganglioside GT1